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Available online 10 November 2015Dysregulated expression of MYC family genes is a hallmark of manymalignancies. Unfortunately, these proteins
are not amenable to blockade by small molecules or protein-based therapeutic agents. Therefore, we must ﬁnd
alternative approaches to target MYC-driven cancers. Ampliﬁcation of MYCN, a MYC family member, predicts
high-risk neuroblastoma (NB) disease. We have shown that R9-caPep blocks the interaction of PCNA with its
binding partners and selectively kills human NB cells, especially those with MYCN ampliﬁcation, and we now
show the mechanism. We found elevated levels of DNA replication stress in MYCN-ampliﬁed NB cells. R9-
caPep exacerbated DNA replication stress inMYCN-ampliﬁed NB cells and NB cells with an augmented level of
MYC by interfering with DNA replication fork extension, leading to Chk1 dependence and susceptibility to
Chk1 inhibition. We describe how these effects may be exploited for treating NB.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Chk11. Introduction
Dysregulated expression of the MYC family oncogenes, including
MYC, MYCN, and MYCL, is a hallmark of malignancy and is involved in
cancer initiation and maintenance (Dang, 2012; Meyer and Penn,
2008). TheMYC family proteins are structurally similar and functionally
equivalent (K.C. et al., 2014) transcription factors that promote S-phase
entry and facilitate DNA replication during stress (Dominguez-Sola and
Gautier, 2014; Dominguez-Sola et al., 2007; Felsher et al., 2000; Mai
et al., 1996), thereby conferring a proliferation and survival advantage
to cancer cells. Proof-of-principle studies demonstrated that blocking
MYC protein function is beneﬁcial to cancer treatment (Soucek et al.,
2008; Soucek et al., 2013). However, ﬁnding small molecule or biologic
inhibitors ofMYChas proven to be a difﬁcult task.MYC is localizedwith-
in nuclei (Smith et al., 2004) and has no deep surface binding pocket
(Nair and Burley, 2003). Therefore, MYC is not amenable to blockade
by small molecules or accessible to neutralization by antibodies. It. This is an open access article underis also difﬁcult to manipulate MYC target genes. The target genes regu-
lated by MYC are from a broad range of functional categories and are
often cell type dependent (Lin et al., 2012; Nie et al., 2012). As a result,
the downstream gene(s) that truly mediates MYC's tumorigenic activi-
ties remains elusive. Despitemore than a decade of effort, noMYC inhib-
itor has reached the clinic. Exploiting functional vulnerabilities caused
by MYC dysregulation may provide a viable alternative to translate the
wealth of MYC-related research into clinical beneﬁt.
Ampliﬁcation of theMYCN oncogene occurs in 20–25% of all neuro-
blastomas (NBs) and correlates with a particularly poor prognosis; it is
the most prominent genetic marker for high-risk NB disease (Maris,
2010). Furthermore, by studying the expression signature ofMYC target
genes, Fredlund et al. found that the combined pathway activity of all
MYC family proteins correlated with clinical risk and poor prognosis in
NB patients independent of MYCN ampliﬁcation (Fredlund et al.,
2008). Current treatment for high-risk NB patients consists of induction
treatment (conventional chemotherapy and surgery with or without
radiotherapy), high-dose chemotherapy and autologous stemcell trans-
plantation (HDCT/autoSCT) as a consolidation treatment, and 13-cis-
retinoic acid treatment to reduce relapse fromminimal residual disease.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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therapy (Bhatnagar and Sarin, 2012). Of the high-risk population that
does respond to induction chemotherapy, a substantial portion relapses,
and relapse occurs despite intensive consolidation and maintenance
therapies (Aaltomaa et al., 1993; Park et al., 2010).
In an effort to develop a novel therapy for treating high-risk NB, we
designed a cell permeable peptide, R9-caPep (Gu et al., 2014), which
contains the L126-Y133 sequence of proliferating cell nuclear antigen
(PCNA). PCNA, through its interaction with more than a dozen of pro-
teins, plays an essential role in DNA synthesis and repair (Maga and
Hubscher, 2003). Inhibition of PCNA is viewed as an effective way to
suppress tumor growth (Stoimenov and Helleday, 2009). The L126-
Y133 peptide region, located within the PCNA's interconnector domain
that mediates the interaction of PCNAwithmany of its binding partners
(Krishna et al., 1994), is differentially modiﬁed between cancerous and
non-malignant cells (Hoelz et al., 2006; Malkas et al., 2006). Therefore,
this peptide region, essential to PCNA function, provides a structural
base for selectively targeting cancer cells. We previously reported that
R9-caPep blocks the interaction of PCNAwith ﬂap structure-speciﬁc en-
donuclease 1 (Fen1), DNA ligase I (LIGI), and DNA polymerase δ in vitro
(Smith et al., 2015) and in vivo (Gu et al., 2014). It selectively kills NB
cells with minimal toxicity to human peripheral blood mononuclear
cells (PBMC) or neural crest stem cells (Gu et al., 2014). Importantly,
we found that MYCN-ampliﬁed NB cell lines are twice as sensitive to
R9-caPep treatment as non-MYCN-ampliﬁed lines (Gu et al., 2014).
To dissect the mechanism that makes MYCN-ampliﬁed NB cells
vulnerable to R9-caPep, we analyzed the expression of biological
markers indicative of replication stress (RS) and DNA damage response
(DDR) (Chanoux et al., 2009; Wang et al., 2006) and found thatMYCN-
ampliﬁed NB cells and tumors contain higher levels of markers indica-
tive of ATR/Chk1 signaling and RS than non-MYCN-ampliﬁed ones, indi-
cating the presence of chronic RS. This ﬁnding also suggests that the
MYCN-ampliﬁed NB cells depend on ATR/Chk1-mediated DDR to prolif-
erate despite high levels of RS. This observation raises the possibility
thatMYCN-ampliﬁed NB cells are intrinsically sensitive to the induction
of additional RS and are susceptible to Chk1 inhibition. Here, we have
demonstrated that R9-caPep interfereswithDNA replication fork exten-
sion and induces RS in MYCN-ampliﬁed cells. In addition, R9-caPep
treatment works synergistically with Chk1 inhibition to exacerbate RS
and killMYCN-ampliﬁedNB cells and other NB cells that express an aug-
mented level of MYC. Based on these observations, we propose that
chronic RS in MYCN-ampliﬁed NB cells is a weak link, and the RS-
induced dependence of MYCN-ampliﬁed NB cells on ATR/Chk1-
mediated DDR is a promising target for treating this devastating disease.
Our study also demonstrated the therapeutic potential of R9-caPep to
attack this weak link for treating MYCN-ampliﬁed NB disease and
other high-risk NB disease that expresses an enhanced level of MYC.
2. Materials & Methods
2.1. Reagents and Cell Lines
The cell permeable peptide, R9-caPep (RDRDRDRDRDRDRDRDRD
CCLGIPEQEY), was created by fusing the L126-Y133 sequence of
human PCNA to the C-terminus of a nine D-arginine sequence (R9)
through a spacer of two cysteines (CC). The peptide was synthesized
by AnaSpec (Fremont, CA). The Chk1 inhibitors, MK-8776 and UCN-
01,were purchased fromSelleckchem (Houston, TX) and EMDMillipore
(Billerica, MA), respectively. siRNAs targetingMYCN and non-targeting
siRNAs were purchased from GE Healthcare (Pittsburgh, PA).
The human NB cell lines, SK-N-DZ, SK-N-BE(2)c, BE(2)c, CHP-212,
IMR-32, SK-N-AS, SK-N-SH, and SH-SY5Y were obtained from
the American Type Culture Collection (ATCC, Rockville, MD). Cells
were maintained in DMEM with 10% fetal bovine serum (FBS), 100
units/ml penicillin, and 100 μg/ml streptomycin in the presence of 5%
CO2 at 37 °C. The non-malignant HCN1-A cortical neuronal cell lineand bone marrow-derived Mesenchymal Stem Cells (hBM-MSCs)
were obtained from the ATCC as well and were cultured according to
the ATCC instructions. The human embryonic progenitor cell line
7SM0032 was acquired from Millipore (Billerica, MA) and grown in
the hEPM-1 Media Kit purchased from the same company.
2.2. siRNA Transfection
SK-N-BE(2)c cells were reverse transfected with siRNAs targeting
MYCN or non-targeting siRNA by Lipofectamine 2000 (Thermo Fisher
Scientiﬁc,) according to themanufacturer's instructions. The transfected
cells were plated at 2.5 × 105 cells/cm2 in a cell culture dish. 48 h after
the initial transfection, cells were detached and reverse transfected
again with the same siRNA. Transfected cells were directly seeded at
1 × 105 cells/cm2 into a 96-well plate. After being allowed to attach
overnight, cells were treated with various concentrations of R9-caPep
for an additional 72 h. The relative abundance of cells was measured
by a CellTiter-Glo assay (Promega, Madison, WI).
2.3. Gene Expression Proﬁle Analysis
A well-annotated microarray dataset consisting of gene expression
proﬁles of 478 NB patient tumor samples was previously published by
Oberthuer, et al. and is accessible through ArrayExpress (E-MTAB-
179). Total cellular RNAs were extracted from 5 MYCN-ampliﬁed NB
cell lines, 3 non-MYCN-ampliﬁed NB cell lines, and 2 non-malignant
cell lines in triplicate, using the RNeasy kit purchased from Qiagen
(Valencia, CA). The gene expression proﬁles of each cell line were ana-
lyzed by hybridizing the labeled cDNA to the Affymetrix Human Gene
Array 1.0. The microarray data were analyzed by the Partek Genomics
Suite 6.6 software (Partek, Saint Louis, MO). Brieﬂy, raw data were nor-
malized and converted into the expression measurements by the RMA
algorithm. The ANOVA model was used to identify genes that were dif-
ferentially expressed between the sample groups.
2.4. Western Blot
Cell extractswere prepared by dissolving cell pellets directly into the
Laemmli sample buffer with 5% DTT. After ultrasonication and boiling,
samples were resolved in a 4–12% SDS polyacrylamide gel and blotted
onto a nitrocellulose membrane. The membrane was blocked with 5%
nonfat dry milk and incubated with an antibody speciﬁc to γH2A.X, total
H2A.X, Chk1, phospho-Chk1 (Ser345), Rad17, cleaved caspase-3, cleaved
PARP1, orβ-actin in theblockingbuffer. All antibodiesused inwesternanal-
yses, except for γH2A.X (EMDMillipore) and Rad17 (LifeSpan Biosciences,
Seattle, WA), were purchased from Cell Signaling Technology (Danvers,
MA). After incubation with peroxidase-conjugated secondary antibodies,
the proteins of interest were detected by chemiluminescence, using an
ECL kit purchased from GE Healthcare (Pittsburgh, PA).
2.5. DNA Combing Analysis
A DNA combing assay was performed to measure the effect of
AOH1160 on replication fork extension, as described (Frum et al.,
2013). Brieﬂy, synchronized S-phase cells were ﬁrst pulsed with CldU,
a modiﬁed thymidine analog, in the absence of AOH1160 for 10 min.
After washing away the unincorporated CIdU, we added another modi-
ﬁed thymidine analog, IdU, to the cells with or without 100 μM of R9-
caPep. After 20 min of incubation, the cells were collected, spotted on
microscope slides, and lysed. The incorporation of CldU and IdU into
DNA was visualized under a ﬂuorescence microscope after the cells
were stained by monoclonal antibodies that are speciﬁc to CldU and
IdU respectively and are linked to different ﬂuorophores: green for
CIdU and red for IdU. The rate of DNA replication fork extension before
and after R9-caPep treatment was estimated by measuring the relative
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ImageJ software (National Institute of Health, Bethesda, MD).
To measure the effect of UCN-01 and R9-caPep on activation of rep-
lication origins, synchronized cells were treated with each or both re-
agents for 12 h and were sequentially labeled by CldU and IdU for
15 min each. Origins were identiﬁed as the center point of CldU
(green)-labeled regions surrounded on both sides by IdU (red)-labeled
regions. The relative distance between adjacent origins on individual ﬁ-
bers was measured using the ImageJ software.
2.6. Immunohistochemistry
The study was carried out in accordance with City of Hope's and Van-
derbilt University's policies governing the use of patient specimens and
PDX tissues, respectively. 5-μm-thick serial sections were made from
formalin-ﬁxed, parafﬁn-embedded patient tumors or PDX tumors. The
γH2A.X-speciﬁc antibody was purchased from Cell Signaling Technology.
Antibodies speciﬁc to Chk1 and phosphorylated Rad17 were purchased
from LifeSpan Biosciences. The staining was detected by the EnVision+
horseradish peroxidase system purchased from Dako (Carpinteria, CA).
Counterstaining was with 50% Mayer's hematoxylin (DAKO) for 3 min.
Slides were visualized and images were acquired on an Aperio® CS2 slide
scanner under a 20× objective lens (Leica, Buffalo Grove, IL).
2.7. Growth Inhibition and Synergism Analysis
Cells were seeded at 1.5 × 103–6 × 103/well depending on the growth
rateofeachcell line ina96-wellplate.Afterbeingallowedtoattachovernight,Fig. 1.MYCN ampliﬁcation is associated with high Chk1 signaling and RS. a) Total RNA extracte
IMR-32), non-MYCN-ampliﬁed NB cell lines (green: SK-N-AS, SK-N-SH, and SH-SY5Y), and non
analysis. The Log2 transformed Chk1 (X-axis) andMYCN (Y-axis)mRNA levels in these cell lines
lines were analyzed by linear regression (r = 0.886). b) Total cell extracts from the indicated c
Rad17. c) A microarray dataset of NB patient specimens (ArrayExpress: E-MTAB-179) was
MYCN ampliﬁcation was graphed with the bottom and top ends of the whiskers representin
non-MYCN-ampliﬁed NB samples. The “low-risk” subset includes patients with stage 1, 2, or 4S
patients with stage 4 non-MYCN-ampliﬁed tumors and above the age of 18months. The p-value
and e) PTX NB tumors were stained with the indicated antibodies, as described in the Material
MYCN-ampliﬁed tumors and the right two columns are sections made from two non-MYCN-amcells were treated with various concentrations of the R9-caPep and/or
Chk1 inhibitors for 72 h. Cell growth was measured by the CellTiter-Glo
assay according to the manufacturer's instructions. The synergism
between the peptide and a Chk1 inhibitor was analyzed according to the
median-effect principle by the CalcuSyn software (Biosoft, Cambridge, UK).3. Results
3.1. Enhanced RS and Chk1 Signaling in MYCN-ampliﬁed NB
To determine the mechanism that makesMYCN-ampliﬁed NB cells
sensitive to R9-caPep, we analyzed the gene expression proﬁles of
5 MYCN-ampliﬁed NB cell lines, 3 non-MYCN-ampliﬁed NB cell lines,
and 2 non-malignant human cell lines. Raw microarray data are
deposited in the Gene Expression Omnibus database (accession no.
GSE66586). We found that NB cells express a higher level of Chk1
mRNA than non-malignant human cells and the Chk1mRNA levels cor-
relate strongly withMYCN expression levels and ampliﬁcation status in
NB cell lines (Fig 1a). Western analysis conﬁrmed thatMYCN-ampliﬁed
cells express a higher level of Chk1 protein than non-MYCN-ampliﬁed
cells and non-malignant cells (Fig 1b). Protein complexes containing
Rad17 assembled at theDNA lesion site are required for ATR/Chk1 phos-
phorylation and activation (Cimprich and Cortez, 2008; Nam and
Cortez, 2011; Zou et al., 2002). MYCN-ampliﬁed cell lines also express
higher levels of phosphorylated Chk1 (p-Chk1) and Rad17, indicating
that ATR/Chk1 signaling is enhanced in MYCN-ampliﬁed NB cells
(Fig. 1b). All the non-MYCN-ampliﬁed NB cell lines included in this
study express an augmented level of MYC (Gumireddy et al., 2003;d fromMYCN-ampliﬁed NB cell lines (blue: SK-N-DZ, SK-N-BE(2)c, BE(2)c, CHP-212, and
-malignant human cell lines (red: HCN1-A and hBM-MSCs) were analyzed by microarray
were graphed. The correlation between relative Chk1 andMYCNmRNA levels in these cell
ell lines were analyzed byWestern blotting to determine the levels of p-Chk1, Chk1, and
analyzed. The relative expression of Chk1 mRNA in patient specimens with or without
g the 5th and 95th percentiles of the expression levels respectively. “All” represents all
non-MYCN-ampliﬁed NB and under the age of 18months. The “high-risk” subset includes
was determined by an unpaired t-test. Serial sectionsmade from d) patient NB specimens
s and Methods. The left two columns in each panel box are serial sections made from two
pliﬁed tumors.
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though the levels of Chk1 signaling components in these non-MYCN-
ampliﬁed cells are lower than those in MYCN-ampliﬁed cells, they are
much higher than the levels in non-malignant neural crest stem cells
(Fig. 1a & b). This result is consistent with the functional overlaps be-
tweenMYCN and MYC and with the observation that the total pathway
signaling of MYC family proteins, determined by the expression of MYC
target genes, are stronger inMYCN-ampliﬁed NB cell lines than in non-
MYCN-ampliﬁed lines (Chayka et al., 2015). To determine if the en-
hanced Chk1 expression observed in the MYCN-ampliﬁed cell lines
also occurs in patient specimens,we analyzed amicroarray dataset pub-
lished by Oberthuer et al. (Oberthuer et al., 2010) consisting of expres-
sion data from 472 NB patients with knownMYCN ampliﬁcation status.
Consistentwith our observations in NB cell lines, Chk1 expression is sig-
niﬁcantly higher inMYCN-ampliﬁed human NB specimens than in non-
MYCN-ampliﬁed specimens (Fig. 1c). We also compared Chk1 mRNA
levels betweenMYCN-ampliﬁed tumors and the high and low-risk sub-
sets of non-MYCN-ampliﬁed tumors (Fig. 1c). Although, in the popula-
tion of non-MYCN-ampliﬁed tumors, the high-risk subset expresses a
signiﬁcantly higher level of Chk1 mRNA than the low-risk subset
(Fig. 1c), Chk1 mRNA levels are higher in MYCN-ampliﬁed tumors
than in the high-risk non-MYCN-ampliﬁed tumors. In the population
of non-MYCN-ampliﬁed tumors, Chk1 mRNA level also correlates with
MYC expression (analysis not shown). These observations are consis-
tent with previous studies of human NB specimens (Cole et al., 2011).
The enhanced signaling of the ATR/Chk1 pathway suggests that
chronic RS may be present in MYCN-ampliﬁed NB cells and that the
cells may depend on ATR/Chk1-mediated DDR to deal with such RS.
To determine whether RS levels and Chk1 signaling are elevated inFig. 2.MYCNoverexpression confers sensitivity to R9-caPep. SK-N-BE(2)c cellswere transfected
after the initial transfection, cellswere reverse transfected again by the same siRNA. a) SK-N-BE(
for 12 h. IntracellularMYCN, γH2A.X, and total H2A.X levelswere determined byWestern blot.
Wear, England) and were presented at the bottom of the panel. b) After the second transfection
were then treated byvarious concentration of R9-caPep for 72h, before their growthwasmeasu
cell populationswere averaged and graphed±standard deviation (S.D.). c)MYCNprotein level
fection were examined byWestern blot.MYCN-ampliﬁed NB tumors, we analyzed intracellular markers of RS
and Chk1 signaling in 27 clinical NB specimens (of which 2 areMYCN-
ampliﬁed and 25 are non-MYCN-ampliﬁed) and in 9 patient-derived xe-
nograft (PDX) tumors (of which 3 areMYCN-ampliﬁed and 6 are non-
MYCN-ampliﬁed) by immunohistochemistry. Strong nuclear staining
of Chk1 was seen in all 5 MYCN-ampliﬁed tumors that we analyzed
(Fig. 1d and e). In contrast, of the 31 non-MYCN-ampliﬁed tumors (25
patient specimens and 6 PDX), only 7 had Chk1 staining in nuclei, al-
though many non-MYCN-ampliﬁed tumors had weak Chk1 staining in
the cytoplasm (Fig. 1d and e). On average, MYCN-ampliﬁed tumors
also had a higher level of γH2A.X (a DNA damage marker) and
phosphor-Rad17 (p-Rad17) than non-MYCN-ampliﬁed tumors (Fig. 1d
and e). Collectively, these results indicate that RS levels are higher and
ATR/Chk1 signaling is more active inMYCN-ampliﬁed tumors.
3.2. MYCN Ampliﬁcation Causes RS and Confers Sensitivity to R9-caPep
To determinewhetherMYCN ampliﬁcation and the resulting protein
overexpression are responsible for chronic RS and enhanced sensitivity
to R9-caPep, we transfectedMYCN-ampliﬁed SK-N-BE(2)c NB cells with
a siRNA (siMYCN) targeting the human MYCN mRNA and examined
the effect on intracellular γH2A.X levels. Cells transfected with a non-
targeting siRNA (siCTL) were used as control. R9-caPep treatment
induced γH2A.X levels in SK-N-BE(2)c cells transfected by siCTL
(Fig. 2a), suggesting that the peptide can cause RS. Downregulation of
MYCN by siMYCN reduced basal γH2A.X levels by about 5 fold in
SK-N-BE(2)c cells (Fig. 2a), indicating that a high level ofMYCN expres-
sion is responsible for the chronic RS and DNA lesions in MYCN-
ampliﬁed cells. R9-caPep treatment increased γH2A.X level by about 3by a siRNA(siMYCN) targetingMYCNmRNAor a non-targeting control siRNA (siCTL). 48h
2)c cells transfected by siMYCNor siCTLwere incubated in the presence of 20 μMR9-caPep
The density levels of γH2A.X and total H2A.Xwere quantiﬁed by TotalLab Quant (Tyne and
, cells were seeded into a 96-well plate directly and allowed to attach overnight. The cells
red by a CellTiter-Glo assay. TheR9-caPep IC50 values from three independently transfected
s in cell lysates extracted fromaliquots of cells at 0, 72, and 144 h after the ﬁrst siRNA trans-
Fig. 3. R9-caPep interferes with replication fork extension. Synchronized SK-N-BE(2)c
cells were sequentially treated with two nucleotide analogs, CldU and IdU, before and
after R9-caPep treatment. Cells sequentially treatedwith the same two nucleotide analogs
without R9-caPep treatment were used as controls. The incorporation of these two
nucleotides, representing replication fork extension before and after R9-caPep treatment
respectively, was visualized by a ﬂuorophore-coupled monoclonal antibody speciﬁc
to CldU (green) or IdU (red). a) Shown are representative images of the labeled
DNA strands from cells treated with or without R9-caPep. b) The lengths of IdU (red
bars) and CldU (green bars) incorporatedDNA segmentsmeasured frommore than 30 in-
dependent DNA strands from cells treated with or without R9-caPep were averaged and
graphed ±S.D.
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siMYCN transfected cells was about a third of the level in control cells
under the same treatment (Fig. 2a), indicating a meaningful contribu-
tion ofMYCN to the total RS and DNA lesion inMYCN-ampliﬁed cells be-
fore and after R9-caPep treatment. Consistent with the effect of MYCN
on intracellular γH2A.X levels, downregulation of MYCN expression by
siMYCN signiﬁcantly increased the IC50 value of R9-caPep in a cell
growth assay (Fig. 2b), indicating that MYCN overexpression confers
sensitivity to R9-caPep. Western analysis conﬁrmed a near depletion
of MYCN protein in cells twice transfected with siMYCN compared
with the level in cells transfected with siCTL over the full experimental
time frame (Fig. 2c).
3.3. R9-caPep Interferes with DNA Replication Fork Extension
The presence of chronic RS in MYCN-ampliﬁed NB cells raises the
possibility that these cells are more sensitive to additional RS induced
by R9-caPep than non-MYCN-ampliﬁed NB cells. To understand the
mechanism by which R9-caPep induces RS, we measured the effects of
R9-caPep on DNA replication fork extension. In this experiment,
synchronized S-phase cells were ﬁrst pulsed with CldU, a modiﬁed
thymidine analog, in the absence of R9-caPep. After washing away the
unincorporated CldU, cells were incubated with another modiﬁed thy-
midine analog, IdU, in the presence or absence of 100 μM of R9-caPep.
The rate of DNA replication fork extension before and after R9-caPep
treatment was estimated by measuring the relative length of CldU-
incorporated DNA strands and adjacent IdU-incorporated DNA strands,
respectively. The DNA replication forks extended at similar rates in the
control and experimental cells before R9-caPep treatment, as indicated
by the similar average lengths of the CldU-incorporated DNA strands
(Fig 3). In contrast, cells treated by R9-caPep contain signiﬁcantly
shorter IdU-incorporated DNA strands than the control cells, indicating
that R9-caPep interferes with the extension of preexisting DNA replica-
tion forks (Fig 3).
3.4. R9-caPep Works Synergistically with Chk1 Inhibitors
The sensitivity of MYCN-ampliﬁed NB cells to R9-caPep-induced RS
and the possible dependence of these cells on Chk1-mediated DDR to
deal with RS strongly suggest a synergism between R9-caPep treatment
and Chk1 inhibition. To test this, we performed a synergism assay based
on the median-effect principle (Chou and Talalay, 1984). In the experi-
ment, cell growth was measured after treatment with 2-fold serial dilu-
tions of R9-caPep and a Chk1 inhibitor [UCN-01 (Graves et al., 2000) or
MK8776 (Guzi et al., 2011)] at a ﬁxed concentration ratio that matches
their respective IC50s. Cells treated by each agent alone were used as
controls. The combination of R9-caPep with UCN-01 or MK8776 signif-
icantly inhibited the growth of twoMYCN-ampliﬁed NB cancer cell lines
using doses of R9-caPep and Chk1 inhibitors that did not signiﬁcantly
affect cell growth (Fig. 4a–c). These growth data were analyzed by the
method developed by Chou et al. (Chou and Talalay, 1984) to determine
synergism. As shown in the bottom panels (Fig. 4a–c), combination
dose pairs ranging from ED50 to ED90 are all plottedwell below their re-
spective additive isoboles with combination indices (CI) between 0.17
and 0.55, indicating synergism between the combined agents.
Since MYC expression is a risk factor in non-MYCN-ampliﬁed high-
risk NB and is associated with augmented Chk1 signaling, we sought
to determine whether R9-caPep can induce RS and confer sensitivity
to Chk1 inhibition in non-MYCN-ampliﬁed cells that express a high
level of MYC. We performed a similar synergism study in SH-SY5Y
cells (Gumireddy et al., 2003; Vandesompele et al., 2003). Although
this non-MYCN-ampliﬁed cell line is less sensitive to treatment by R9-
caPep alone thanMYCN-ampliﬁed cell lines (Gu et al., 2014), combined
treatment by R9-caPep and UCN-01worked synergistically to inhibit its
growth (Fig. 4d).Chk1-mediated DDR can enable cells to survive RS by stabilizing
existing replication forks and preventing excessive ﬁring of new replica-
tion origins (McNeely et al., 2010; Seiler et al., 2007). In addition, Chk1
signaling plays a critical role in regulating the initiation of normal DNA
replication (Maya-Mendoza et al., 2007). Unscheduled replication initi-
ation causes DNA lesions and genome instability. To determine the
mechanism by which R9-caPep and Chk1 inhibitors work synergistical-
ly to kill cancer cells, we sought to determine their effects on the regu-
lation of replication origin ﬁring. The average distance between
neighboring replication origins is signiﬁcantly shorter in both MYCN-
ampliﬁed SK-N-BE(2)c and MYC-expressing SH-SY5Y cells treated by
UCN-01 and R9-caPep than in the corresponding cells treated by either
agent alone, indicating that these two agents work synergistically to
dysregulate the control of replication origin ﬁring (Fig. 5b and c). The
amount of DNA lesions indicated by the intracellular γH2A.X levels is
much higher in cells treated by both R9-caPep and UCN-01 than by
each agent alone (Fig 5d), indicating that interference with replication
by R9-caPep leads to stalling of replication forks and accumulation of
double-strandedDNA break in the absence of Chk1 signaling. Combined
treatment by R9-caPep and UCN-01 also caused higher levels of cleaved
Fig. 4. R9-caPepworks synergisticallywith Chk1 inhibitors. Sk-N-BE(2)c (Panels a and c), SK-N-DZ (Panel b), and SH-SY5Y (Panel d)NB cellswere treatedwith 2-fold serial dilutions of R9-
caPep and UCN-01 (triangles in panels a, b, and d) or R9-caPep and MK-8776 (triangles in panel c) at a ﬁxed concentration ratio. Cells treated with the same concentrations of R9-caPep
(squares), UCN-01 (circles), orMK-8776 (circles) alonewere used as control. Cellswere cultured in the presence of the reagents for 3 days and their growthwas determined by a CellTiter-
Glo assay (Promega). Top: the relative abundance of cells in triplicates under each treatment conditions was averaged and graphed ±S.D. Bottom: conservative isobolograms were
graphed and CI values were calculated for each study by CalcuSyn. Blue: ED90; green: ED75; and red: ED50.
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ptosis (Fig 5d).
4. Discussion
Numerous studies have shown that the dysregulation of MYC family
proteins underlies the pathogenesis and aggressiveness of many malig-
nancies. It is well established that inhibition of MYC protein function is
beneﬁcial to cancer treatment. In the case of NB, stable downregulation
of MYCN mRNA by lentivirus-based RNAi inhibits the growth of
human MYCN-ampliﬁed NB cells in vitro and in vivo (Jiang et al.,
2011). However, targetingMYCproteins directly has yet to be successful
as a therapeutic approach in spite of efforts for more than a decade. We
previously reported thatMYCN-ampliﬁedNB cells are particularly sensi-
tive to R9-caPep (Gu et al., 2014). Here, we have demonstrated that
MYCN overexpression is responsible for conferring sensitivity to R9-
caPep in NB cells. We have also observed that MYCN-ampliﬁed or
MYC-ampliﬁed small cell lung cancer (SCLC) cells are more sensitive
to R9-caPep than SCLC cells containingno ampliﬁcation of anyMYC fam-
ily genes (data will be published separately). This raises the possibility
that R9-caPepmay selectively kill a broad range of cancers that is driven
by the MYC family proteins. Based on the published crystal structure,
the L126-Y133 peptide region of PCNA forms part of a pocket suitable
for binding by small molecules (Punchihewa et al., 2012). The effective-
ness of R9-caPep in inhibitingMYCN-ampliﬁed NB cells not only shows
the therapeutic potential of this peptide, but also provides proof-of-
concept evidence that targeting a well deﬁned region of PCNA may
lead to an effective therapy for treating MYC-driven cancers.
We compared gene expression proﬁles from multiple NB cell lines
and non-malignant cell lines and found that the expression of Check-
point kinase 1 (Chk1) is signiﬁcantly higher in MYCN-ampliﬁed cell
lines than in non-MYCN-ampliﬁed cell lines or non-malignant humancells. Analysis of microarray data previously published by Oberthuer
et al. (Oberthuer et al., 2010) also revealed a strong correlation between
Chk1 expression and MYCN ampliﬁcation in patient samples. In non-
MYCN-ampliﬁed tumors, Chk1 expression is signiﬁcantly higher in the
high-risk subset than in the low-risk subset and correlateswithMYC ex-
pression. Chk1, whose expression and activity correlates with RS and
the ensuing DDR (Bartkova et al., 2005), plays a critical role in the ATR
signaling pathway that senses RS and arrests the cell cycle, thereby
allowing cells time to deal with RS and to resolve DNA lesions
(Abraham, 2001; Smith et al., 2010). After DNA replication forks en-
counter lesions and stall, a protein complex, consisting of Rad17 and
the Replication Factor C (RFC), recognizes junctions of single stranded
and double-stranded DNAs and recruits the 9-1-1 checkpoint sliding
clamp complex to the arrested forks (Bermudez et al., 2003; Ellison
and Stillman, 2003). Whereas Rad17 may function as a tumor suppres-
sor (Bric et al., 2009), suppression of Rad17 beyond a crucial threshold
could also be deleterious to proliferation (Bric et al., 2009). In addition,
depletion of Rad17 sensitizes pancreatic cancer cells to gemcitabine
(Fredebohm et al., 2013), indicating a critical role of Rad17 in dealing
with RS. Both the Rad17 checkpoint loading complex and the 9-1-1
complex are required for ATR activation (Zou et al., 2002). The ATR
checkpoint signaling is transduced through phosphorylation of Chk1,
which in turn activates a collection of Chk1 substrates that stabilize rep-
lication forks and arrest the cell cycle (Cimprich and Cortez, 2008; Nam
and Cortez, 2011).
Mechanistically, R9-caPep is able to interfere with DNA replication
fork extension and to induce RS in NB cells. It has been shown
that MYC proteins, including MYCN, promote S-phase entry and
inhibit G1 arrest after DNA damage. In the MYCN-ampliﬁed NB cell
line, SK-N-BE(2)c, knockdown ofMYCN expression by siRNA can restore
DNA damage-induced G1 arrest, indicating a causal relationship be-
tween MYCN overexpression and dysregulation of the G1 checkpoint
Fig. 5.Dysregulation of replication initiation and induction of DNA damage and apoptosis by R9-caPep and Chk1 inhibitors. b) SK-N-BE(2) cells or c) SH-SY5Y cells were incubated for 12 h
with 7.8 nMUCN-01, 30 μMR9-caPep, or 7.8 nMUCN-01 and 30 μMR9-caPep for 12 h. Untreated corresponding cells were used as controls. Cells were sequentially labeled with CldU and
IdU for 15min each. Following incubationwith the nucleotide analogs, the cellswere stained byﬂuorophore-coupledmonoclonal antibodies to visualized CIdU and IdU incorporation. The
relative distance between two neighboring replication origins wasmeasured as illustrated in panel a. The distances between two neighboring origins from at least 15 DNA segments from
cells under each treatment conditionwere graphed. d) SK-N-BE(2)c (left) or SH-SY5Y (right) cellswere treated by7.8 nMUCN-01, 30 μMR9-caPep, or both for 12 h. The intracellular levels
of the indicated proteins were determined byWestern blot.
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likely to enter S-phase with unrepaired DNA damage. These cells are
more like to experience RS and to be susceptible to further induction
of RS by therapeutic agents. To verify this hypothesis and to exploit
the vulnerability of MYCN-ampliﬁed NB for a therapeutic purpose, we
analyzed the biomarkers indicative of RS in NB cell lines and tumor tis-
sues and found thatMYCN ampliﬁcation is associatedwith a higher level
of γH2A.X and more active Chk1 signaling. An augmentedMYC expres-
sion is also associated with an enhanced Chk1 level in non-MYCN-
ampliﬁed NB tumors. Collectively, these experiments revealed that the
presence of RS and the dependence on Chk1 are crucial vulnerabilities
inMYCN-ampliﬁed and MYC-expressing cells and can be used to target
these cells for destruction.
Based on the current study, we propose a workingmodel (Fig. 6), in
which the MYC family oncoproteins dysregulate the G1/S checkpoint,
inhibit G1 arrest after DNA damage, and promote S-phase entry. Conse-
quently, NB cells withMYCN ampliﬁcation or enhancedMYC expression
are more likely to enter S-phase with unrepaired DNA damage andexperience chronic RS. They aremore dependent on theATR/Chk1 path-
way to resolve DNA lesions during replication. The cell-permeable R9-
caPep can exacerbate chronic RS in these cells by interfering with DNA
replication fork extension and HR-mediated DSB repair (Gu et al.,
2014). We speculate that the presence of a high level of chronic RS
makes these cells susceptible to additional RS induced by R9-caPep
treatment. Additional RS induced by R9-caPep may overwhelm
the DNA repair capacity and induce cell death through apoptosis.
Alternatively, a low dose of R9-caPep may not kill cells directly, but
makes cells more dependent on ATR/Chk1-mediated DDR and more
susceptible to inhibition of the ATR/Chk1 pathway. Consistent with
such a scenario, we demonstrated that R9-caPep works synergistically
with Chk1 inhibitors to induce DNA lesions and kill cells with MYCN
ampliﬁcation or enhanced MYC expression. Exploiting the vulnerability
associated with an augmented total MYC pathway activity in NB
to interference with DNA replication and induction of RS, as well as
Chk1 inhibition, may lead to an effective way of treating this type of
cancer.
Fig. 6. A working model for exploiting RS inMYCN-ampliﬁed or MYC-expressing NB cells.
Cell cycle checkpoints play a critical role in maintaining genome integrity. Members of
MYC family proto-oncogenes promote cell growth by dysregulating the G1/S checkpoint
and inhibiting G1 arrest after DNA damage. Therefore, cells overexpressing MYC family
proteins aremore likely to enter S-phasewith unrepairedDNAdamages and to experience
RS. R9-caPep induces additional RS by interfering with replication fork extension and by
blocking HR-mediated DSB repair (Gu et al., 2014), making cells dependent on ATR/
Chk1-mediated DDR to prevent the collapse of stalled replication forks and to resolve
DNA lesions. By inducing RS and inhibiting DDR, R9-caPep and Chk1 inhibitors work syn-
ergistically in causing DSB and apoptosis. Such a synergism may provide an effective way
of treatingMYCN-ampliﬁed NB and other high-risk NB that expresses an augmented level
of MYC.
1930 L. Gu et al. / EBioMedicine 2 (2015) 1923–1931Numerous studies in recent years have validated Chk1 as an attrac-
tive anti-cancer target [reviewed in (Ma et al., 2011)].Whereas the clin-
ical development of the ﬁrst Chk1 inhibitor, UCN-01, was hindered by
its unfavorable pharmacokinetics, a new generation of selective Chk1
inhibitors is currently under clinical or preclinical development
(Maugeri-Sacca et al., 2013). It has been shown that Chk1 inhibitors
work synergistically with a broad range of DNA-damaging agents
(Guzi et al., 2011; Karp et al., 2012; Zabludoff et al., 2008). However,
all DNA-damaging agents, including chemotherapy and radiation thera-
py regimens, involve considerable harm to normal tissues. There is also
a high risk of developing resistance to these drugs through mutations,
which result from the genetic instability inherent to many cancers and
from redundancy in DNA synthesis and repair pathways. Recent ad-
vancements in protein and peptide delivery technology have made
peptide-based therapy feasible. Several protein and peptide-based
drugs have successfully reached markets or are currently working
their way through different stages of clinical trials (Stevenson, 2009).
The ability of R9-caPep to target an essential cellular apparatus and to
induce RS in cancer cells without signiﬁcant toxicity to non-malignant
cells (Gu et al., 2014; Lingeman et al., 2014; Smith et al., 2015) makes
it a promising candidate to combinewith Chk1 inhibitors in order to de-
liver synthetic lethality to cancer cells, especially those driven by the
MYC family proteins.
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